119 related articles for article (PubMed ID: 22419448)
1. Susceptibility loci affecting ERBB2/neu-induced mammary tumorigenesis in mice.
Quan L; Dittmar A; Zhou Y; Hutson A; Stassen AP; Demant P
Genes Chromosomes Cancer; 2012 Jul; 51(7):631-43. PubMed ID: 22419448
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice.
Ritland SR; Rowse GJ; Chang Y; Gendler SJ
Cancer Res; 1997 Aug; 57(16):3520-5. PubMed ID: 9270023
[TBL] [Abstract][Full Text] [Related]
3. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
4. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
5. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
6. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
Jacquemart IC; Springs AE; Chen WY
Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
[TBL] [Abstract][Full Text] [Related]
7. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
8. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4.
Jackson-Fisher AJ; Bellinger G; Shum E; Duong JK; Perkins AS; Gassmann M; Muller W; Kent Lloyd KC; Stern DF
Oncogene; 2006 Sep; 25(41):5664-72. PubMed ID: 16652155
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
[TBL] [Abstract][Full Text] [Related]
12. Haploinsufficiency of the Nijmegen breakage syndrome 1 gene increases mammary tumor latency and metastasis.
Wan R; Crowe DL
Int J Oncol; 2012 Jul; 41(1):345-52. PubMed ID: 22576691
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain.
Blackburn AC; McLary SC; Naeem R; Luszcz J; Stockton DW; Donehower LA; Mohammed M; Mailhes JB; Soferr T; Naber SP; Otis CN; Jerry DJ
Cancer Res; 2004 Aug; 64(15):5140-7. PubMed ID: 15289317
[TBL] [Abstract][Full Text] [Related]
14. Opposite effects of modifiers of the ApcMin mutation in intestine and mammary gland.
Czarnomska A; Krysiak E; Piskorowska J; Sitarz M; Pysniak K; Pilcík T; Demant P
Cancer Res; 2003 Aug; 63(15):4533-7. PubMed ID: 12907628
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel modifier loci of Apc Min affecting mammary tumor development.
Wang H; Teske D; Tess A; Kohlhepp R; Choi Y; Kendziorski C; Moser AR
Cancer Res; 2007 Dec; 67(23):11226-33. PubMed ID: 18056448
[TBL] [Abstract][Full Text] [Related]
16. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
17. Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci.
Cool M; Depault F; Jolicoeur P
Genes Chromosomes Cancer; 2006 Feb; 45(2):191-202. PubMed ID: 16258954
[TBL] [Abstract][Full Text] [Related]
18. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers.
Andrechek ER; Laing MA; Girgis-Gabardo AA; Siegel PM; Cardiff RD; Muller WJ
Cancer Res; 2003 Aug; 63(16):4920-6. PubMed ID: 12941816
[TBL] [Abstract][Full Text] [Related]
20. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis.
Rowse GJ; Ritland SR; Gendler SJ
Cancer Res; 1998 Jun; 58(12):2675-9. PubMed ID: 9635596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
